Tango Therapeutics(TNGX)
$22.11-2.06 (-8.52%)
TNGX
Tango Therapeutics stock drug pipeline
$22.11
At close:-2.06 (-8.52%)
Want to see TNGX full AI Analyst Report?
Tango Therapeutics (TNGX) Drug Pipeline
546 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Rmc-6236, Tng462, Rmc-9805 | Pancreatic Cancer Metastatic, Lung Cancer, Nsclc, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma, Ras Mutation, Mtap Deletion, Thoracic Cancer | phase1AndPhase2 | Recruiting | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Mar 28, 2025 | ― |
| Tng462, S095035 | Mtap-Deleted Solid Tumors | phase1AndPhase2 | Recruiting | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Dec 18, 2023 | ― |
| Pembrolizumab, Tng260 | Non Small Cell Lung Cancer, Lung Cancer, Solid Tumors, Adult, Lung Adenocarcinoma | phase1AndPhase2 | Recruiting | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Apr 18, 2023 | ― |
| Pembrolizumab, Tng462 | Locally Advanced Solid Tumor | phase1AndPhase2 | Recruiting | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Jan 30, 2023 | ― |
| Tng908 | Locally Advanced Solid Tumor | phase1AndPhase2 | Active Not Recruiting | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Feb 18, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Rmc-6236, Tng462, Rmc-9805 | phase1AndPhase2 | Pancreatic Cancer Metastatic, Lung Cancer, Nsclc, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma, Ras Mutation, Mtap Deletion, Thoracic Cancer | Recruiting | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Mar 28, 2025 | ― |
| Tng462, S095035 | phase1AndPhase2 | Mtap-Deleted Solid Tumors | Recruiting | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Dec 18, 2023 | ― |
| Pembrolizumab, Tng260 | phase1AndPhase2 | Non Small Cell Lung Cancer, Lung Cancer, Solid Tumors, Adult, Lung Adenocarcinoma | Recruiting | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Apr 18, 2023 | ― |
| Pembrolizumab, Tng462 | phase1AndPhase2 | Locally Advanced Solid Tumor | Recruiting | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Jan 30, 2023 | ― |
| Tng908 | phase1AndPhase2 | Locally Advanced Solid Tumor | Active Not Recruiting | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Feb 18, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Tango Therapeutics, Inc. (TNGX) have in its pipeline
Tango Therapeutics TNGX is currently developing the following drugs: Rmc-6236, Tng462, Rmc-9805, Tng462, S095035, Pembrolizumab, Tng260, Pembrolizumab, Tng462, Tng908. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

